Site of action of a pentapeptide agonist at the glucagon-like peptide-1 receptor. Insight into a small molecule agonist-binding pocket
Graphical abstract
Section snippets
Acknowledgments
This work was supported by grants from American Diabetes Association (1-08-RA-42) and the National Institutes of Health (DK46577). The authors thank M. L. Augustine and A. M. Ball for excellent technical assistance.
References and notes (20)
- et al.
Biochem. Pharmacol.
(2006) - et al.
J. Biol. Chem.
(2002) - et al.
J. Biol. Chem.
(2009) - et al.
Structure
(2010) - et al.
J. Biol. Chem.
(2010) - et al.
Trends Biochem. Sci.
(2009) - et al.
J. Biol. Chem.
(2011) - et al.
J. Biol. Chem.
(2004) - et al.
J. Biol. Chem.
(1998) - et al.
J. Biol. Chem.
(2010)
Cited by (6)
Extending the Structural View of Class B GPCRs
2017, Trends in Biochemical SciencesCitation Excerpt :Comparison of the role of these conserved residues in structural interactions in inactive and active receptor conformations of CRF1, CTR, GCGR, and GLP-1R [6–8,10,12–14] provide insights into the activation mechanisms of class B GPCRs, including the roles of a central polar network, a transmission switch, and intracellular polar networks (Box 1 and Figure 2). The importance of residues R2.46b, H2.50b, N3.43b, Y/F3.44b, E3.50b, N5.50b, T6.42b, H6.52b, G7.50b, and Y7.57b in these structural interaction networks are consistent with class B GPCR mutation studies showing that mutation of these residues alters receptor signaling efficacy or agonist potency [10,17–23]. Furthermore, several of these residues are stabilizing mutations in inactive NAM-bound CRF1 (Y3637.57bA) [8] and GCGR (R1732.46bA) [7] structures as well as inactive NAM-bound (G3616.50bC/I3175.47bC) and active (G3616.50bA, H3636.52bV, V4058.50bA) [10,12] agonist peptide 5-bound GLP-1R crystal structures.
A Novel Peptide with Similar Pharmacology to Exenatide in Rodents as GLP-1 Receptor Agonist
2018, International Journal of Peptide Research and TherapeuticsGlucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes
2016, Pharmacological ReviewsStructural and functional insights into the juxtamembranous amino-terminal tail and extracellular loop regions of class B GPCRs
2014, British Journal of PharmacologyPhysiology and emerging biochemistry of the glucagon-like peptide-1 receptor
2012, Experimental Diabetes Research